This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients. (IDOvaccine)

This study has been completed.
Information provided by (Responsible Party):
Inge Marie Svane, Herlev Hospital Identifier:
First received: May 10, 2010
Last updated: August 17, 2015
Last verified: August 2015

Title: IDO peptid vaccination in combination with immune stimulating agent Aldara and the adjuvant Montanide, for treatment of patients with locally advanced or metastatic non small-cell lung cancer. A first-in-man phase I trial.

Hypothesis: In this trial the investigators assess a new immunotherapeutic strategy targeting the immune inhibiting enzyme, IDO to investigate the potential of vaccination against IDO as a possible anticancer target.

Condition Intervention Phase
NSCLC Lung Cancer Biological: IDO peptide vaccination Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: IDO Peptid Vaccination in Combination With Immune Stimulating Agent Aldara and the Adjuvant Montanide, for Treatment of Patients With Locally Advanced or Metastatic Non Small-cell Lung Cancer. A First-in-man Phase I Trial.

Resource links provided by NLM:

Further study details as provided by Inge Marie Svane, Herlev Hospital:

Primary Outcome Measures:
  • evidence of toxicity [ Time Frame: 12 months ]
    CTCAE = Common Terminology Criteria for Adverse Events v. 3.0 will be used for registration of toxicity

Secondary Outcome Measures:
  • evaluation of immunological and clinical responses [ Time Frame: 18 months ]
    immunological assays will be used to identify immunological responses. CT scans will be used for evaluation of clinical responses.

Enrollment: 14
Study Start Date: June 2010
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Indeolamine 2,3 deoxygenase
To inhibit immune suppression and tolerance, by blocking the IDO enzyme with vaccination against IDO.
Biological: IDO peptide vaccination
Vaccination every second week

Detailed Description:

Background: Non small-cell lung cancer (NSCLC) is a common disease with a poor prognosis when locally advanced or metastasized, despite advances in surgery, chemo- and radiation therapy.

In this trial the investigators assess a new immunotherapeutic strategy targeting the immune inhibiting enzyme, IDO to investigate the potential of vaccination against IDO as a possible anticancer target.

IDO has recently been recognized as an important factor in immune regulation and development of immune tolerance in the microenvironment of cancer cells. Cells that represent IDO at their surface are known to inhibit the immune system. IDO expression is seen both in cancer cells and antigen presenting cells. The vaccination against IDO expressing cells is therefore two-sided. The vaccination therapy is thought to block the development of immune tolerance induced by IDO expressing cells. At the same time the investigators aim to stimulate the production of IDO specific T-cells, hence facilitating the elimination of IDO positive tumour cells. The primary end points are safety and toxicity evaluation. Secondary end points are immunological and clinical response.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

1. Histological or cytological verified non small cell lung cancer 2. Metastatic or locally advanced incurable stage III-IV NSCLC 3. Patients need to be off chemotherapy treatment 4. Evaluable disease according to RECIST V. 1,1 criteria 5. Patients must be HLA-A2 positive 6. Patients > 18 years old 7. Performance status 0-1 8. Life expectancy of > 3 months 9. Acceptable bone marrow function, defined as

a. White blood cell count > 2,5 * 109 /l b. Neutrophil count> 1,5 * 109 /l c. Platelet count > 75 * 109/l 10. Creatinin measured < 2,5 * upper limit value 11. Acceptable liver function, defined as

  1. ASAT < 100 U/L
  2. Bilirubin < 30 U/L 12. Women with child-bearing potential must have controlled s-hcg before inclusion 13. Patients must provide written informed concent before inclusion 13. Termination of chemotherapy treatment > 28 days before inclusion

    14. Termination of radiotherapy treatment > 28 days before inclusion

    15. Inclusion at least > 4 weeks after complicated gastric surgery

    Exclusion Criteria:

    1. Other malignancies except from non-melanoma skin cancer in the previous 5 years until study inclusion
    2. Brain metastasis are allowed after radical excision, and if the patient at least 1 month afterwards is not in clinical or radiographic progression
    3. Patients with active gastric ulcer disease; patients taking antacid treatment can be included.
    4. Severe medical condition, severe asthma, severe COLD, severe arteriosclerosis or diabetic disease
    5. Acute or chronic infection (ie. HIV, hepatitis, tuberculosis)
    6. Severe allergic reaction or previous anaphylactic shock
    7. Autoimmune diseases (ie. autoimmune neutropenia/thrombopenia, hæmolytic anaemia, systemic lupus erythematosis, Sjøgrens disease, sclerodermia, Goodpastures syndrome, Addisons disease, active Graves disease)
    8. Pregnant or lactating women
    9. Psychiatric disease, which can influence compliance
    10. Known hypersensitivity towards the adjuvance Montanide, the Aldara creme, or adhesive tape.
    11. Treatment with immunosuppressive therapy (ie. dexamethasone, methotrexate)
    12. Treatment with other experimental therapy
    13. Treatment with other anti-cancer therapy, except from treatment of osteoporosis
    14. No systemic chemotherapy, immunotherapy or radiation therapy (except locally) are allowed until 28 days before inclusion.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01219348

Center for Cancer ImmuneTherapy
Herlev, Copenhagen, Denmark, 2730
Center for Cancer Immune Therapy, Dept. og Haematology/Oncology
Copenhagen, Herlev, Copenhagen, Denmark, 2730
Sponsors and Collaborators
Inge Marie Svane
Principal Investigator: Trine Zeeberg Iversen, MD Center for Cancer Immune Therapy
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Inge Marie Svane, Prof., MD, PhD, Herlev Hospital Identifier: NCT01219348     History of Changes
Other Study ID Numbers: LU 1006 - IDO
Study First Received: May 10, 2010
Last Updated: August 17, 2015

Keywords provided by Inge Marie Svane, Herlev Hospital:
IDO enzyme
Vaccination trial
Indeolamine 2,3 dioxygenase = IDO

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Immunologic Factors
Physiological Effects of Drugs processed this record on September 21, 2017